<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687141</url>
  </required_header>
  <id_info>
    <org_study_id>D0190C00006</org_study_id>
    <secondary_id>EudractCT 2007-004598-25</secondary_id>
    <nct_id>NCT00687141</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-blind (with-in Panel), Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Healthy Elderly Volunteers After Oral Multiple Ascending Doses of AZD0328</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to investigate the safety and tolerability of AZD0328
      following once-daily dosing for 13 days in elderly healthy volunteers and to define maximum
      tolerated dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of AZD0328 by assessment of vital signs, laboratory variables and ECG</measure>
    <time_frame>Assessments taken at visit 1 (enrolment), during visit 2 (residential period) and follow up visit 3.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of AZD0328 by assessment of adverse events</measure>
    <time_frame>Non serious adverse events will be collected from the start of residential period until the end of the study. Serious adverse events will be collected from signing of consent until end of study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the single and multiple dose pharmacokinetics (PK) of AZD0328</measure>
    <time_frame>PK sampling taken at defined timepoints during residential period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the cognitive dose response relationship for AZD0328</measure>
    <time_frame>Psychometric test battery performed at defined timepoints during residential period.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0328</intervention_name>
    <description>Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally as a solution once per day on day 1, and then day 3 through to day 14.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed informed consent

          -  Clinically normal physical findings, laboratory values, vital signs and resting ECG as
             judged by the investigator

        Exclusion Criteria:

          -  History of clinically significant cardio- or cerebrovascular, pulmonary, renal,
             hepatic, neurological, mental or gastrointestinal disorder or any other major disorder

          -  History of severe allergy/hypersensitivity or symptoms/signs of ongoing
             allergy/hypersensitivity

          -  Intake of any prescribed medicine or St John's Wort, except for occasional paracetamol
             and nasal anticongestant, within 3 weeks or use of over-the-counter drugs within 2
             weeks before the first administration of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Kühn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles ABStrandbodgatan 1S-753 23 Uppsala</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erik Eliasson, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca R&amp;D SödertäljeMedical Science S-151 85 Södertälje Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lulea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <last_update_submitted>December 8, 2010</last_update_submitted>
  <last_update_submitted_qc>December 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Didier Meulien, M.D., Medical Science Director, Emerging Neuroscience</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>AZD0328</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

